中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

文献类型:期刊论文

作者Xu, Chunwei48,49; Si, Lu50; Wang, Wenxian51; Li, Ziming52; Song, Zhengbo51; Wang, Qian53; Liu, Aijun54; Yu, Jinpu55; Fang, Wenfeng56; Zhong, Wenzhao57
刊名THORACIC CANCER
出版日期2022-09-20
ISSN号1759-7706
关键词fusion precision medicine solid tumor targeted therapy tyrosine receptor kinase
DOI10.1111/1759-7714.14644
通讯作者Zhang, Xiaotian(zhangxiaotianmed@163.com) ; Song, Yong(yong.song@nju.edu.cn) ; Lu, Yuanzhi(yuanzhi.lu@jnu.edu.cn)
英文摘要Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first "tumor agnostic" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, and (DNA and/or RNA-based) next-generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first- and second-generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
WOS关键词INFANTILE FIBROSARCOMA ; MESOBLASTIC NEPHROMA ; MOLECULAR-DETECTION ; ANCHORED MULTIPLEX ; KINASE ; EXPRESSION ; MUTATIONS ; FAMILY ; INHIBITION ; RECEPTORS
WOS研究方向Oncology ; Respiratory System
语种英语
出版者WILEY
WOS记录号WOS:000855706000001
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/128990]  
专题中国科学院合肥物质科学研究院
通讯作者Zhang, Xiaotian; Song, Yong; Lu, Yuanzhi
作者单位1.Tianjin Med Univ Canc Inst & Hosp, Dept Integrat Oncol, Tianjin, Peoples R China
2.Xiamen Univ, Affiliated Hosp Med 1, Dept Med Oncol, Xiamen, Peoples R China
3.China Med Univ, Dept Med Oncol, Canc Hosp, Shenyang, Peoples R China
4.Univ Chinese Acad Sci, Zhejiang Key Lab Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
5.Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China
6.Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
7.Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
8.Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China
9.Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China
10.Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Peoples R China
推荐引用方式
GB/T 7714
Xu, Chunwei,Si, Lu,Wang, Wenxian,et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China[J]. THORACIC CANCER,2022.
APA Xu, Chunwei.,Si, Lu.,Wang, Wenxian.,Li, Ziming.,Song, Zhengbo.,...&Lu, Yuanzhi.(2022).Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.THORACIC CANCER.
MLA Xu, Chunwei,et al."Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China".THORACIC CANCER (2022).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。